Last reviewed · How we verify
DE-127 Ophthalmic Solution medium dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
DE-127 Ophthalmic Solution medium dose (DE-127 Ophthalmic Solution medium dose) — Santen Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DE-127 Ophthalmic Solution medium dose TARGET | DE-127 Ophthalmic Solution medium dose | Santen Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DE-127 Ophthalmic Solution medium dose CI watch — RSS
- DE-127 Ophthalmic Solution medium dose CI watch — Atom
- DE-127 Ophthalmic Solution medium dose CI watch — JSON
- DE-127 Ophthalmic Solution medium dose alone — RSS
Cite this brief
Drug Landscape (2026). DE-127 Ophthalmic Solution medium dose — Competitive Intelligence Brief. https://druglandscape.com/ci/de-127-ophthalmic-solution-medium-dose. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab